Elevated Maternal IL-16 Levels, Enhanced IL-16 Expressions in Endothelium and Leukocytes, and Increased IL-16 Production by Placental Trophoblasts in Women with Preeclampsia

Yang Gu, David F. Lewis, Kelli Deere, Lynn J. Groome and Yuping Wang

*J Immunol* 2008; 181:4418-4422; doi: 10.4049/jimmunol.181.6.4418

http://www.jimmunol.org/content/181/6/4418

References

This article cites 21 articles, 6 of which you can access for free at: http://www.jimmunol.org/content/181/6/4418.full#ref-list-1

Subscription

Information about subscribing to *The Journal of Immunology* is online at: http://jimmunol.org/subscription

Permissions

Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts

Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Elevated Maternal IL-16 Levels, Enhanced IL-16 Expressions in Endothelium and Leukocytes, and Increased IL-16 Production by Placental Trophoblasts in Women with Preeclampsia

Yang Gu, David F. Lewis, Kelli Deere, Lynn J. Groome, and Yuping Wang

Cytokine IL-16 plays an important role in innate immune responses. However, little information is available about IL-16 function in human pregnancy. In this study, we collected maternal blood samples from 125 pregnant women between 26 and 41 wk of gestation, 63 from normal pregnant women and 62 from women with preeclampsia (PE). Serum IL-16C levels were measured by ELISA. We also examined IL-16C and IL-16N immunostaining in maternal vessels and protein expression in leukocytes from normal and PE pregnant women. In addition, IL-16C production by placental trophoblasts was also determined. Our results showed that IL-16C levels were significantly higher in severe PE than in mild PE and normal pregnant controls, 515 ± 58 vs 287 ± 46 (p < 0.05) and 163 ± 9 pg/ml (p < 0.01), respectively, indicating that increased IL-16 levels in PE is associated with the severity of the disease. There was no difference for the IL-16C levels in normal pregnant women throughout the third trimester. The correlation of maternal IL-16C levels with labor and body mass index was also analyzed. IL-16C levels were neither associated with labor nor associated with body mass index. Moreover, increased IL-16C immunostaining in maternal vessels and enhanced IL-16C protein expression in leukocytes were observed in PE. We also found that IL-16C production was increased by trophoblasts from PE placentas. Our study demonstrated up-regulation of the IL-16 profile in both the maternal and the placental systems in PE, suggesting that IL-16 could be an important cytokine engaged in the altered immune system and exaggerated inflammatory response in PE syndrome. The Journal of Immunology, 2008, 181: 4418–4422.
Maternal serum IL-16 concentrations and placental trophoblast IL-16 expression were measured by ELISA. The DuoSet IL-16 ELISA Development kit (DY316) was purchased from R&D Systems. The assay procedures followed the manufacturer’s instruction. The range of a standard curve was 20 pg/ml for IL-16N and 5 µg/ml for IL-16C. A total of 12 tissue sections were examined, 6 from normal pregnancies and 6 from women with PE. Stained slides were viewed by an Olympus microscope (Olympus IX 71) and images were captured by a digital camera, which was linked to a PC computer by Picture Frame software (Uptronics). Slides were also subject to immunostaining with mAb against CD31. Slides stained with secondary Ab only were used as a negative control.

**IL-16 protein expression**

Leukocytes were extracted from maternal blood as previously described (15), and total cellular protein was obtained by using an ice-cold lysis buffer containing 50 mmol/l Tris-HCl (pH 7.6), 1% Triton X-100, 0.5% Nonidet P-40, 1 mmol/l PMSF, and 0.5% mmol/l iDTT. An aliquot of total leukocyte protein extract (15 µg per sample) was subjected to electrophoresis on 12% polyacrylamide gels using a Miniprotein 3 gel running system (Bio-Rad) and then transferred to nitrocellulose membrane. The membranes were probed with both IL-16C and IL-16N Abs (Santa Cruz Biotechnology). The bound Abs were visualized with an enhanced chemiluminescent ECL deletion Kit (Amersham Biosciences). Nitrocellulose membranes were stripped and blocked before they were probed again with different primary Abs. The density was scanned and analyzed by NIH Image 1.16. Relative density for IL-16 expression was normalized by β-actin expression for each sample. A total of nine leukocyte samples were examined, five from normal pregnancies and four from women with PE.

**Placental trophoblast isolation and culture**

Placentas were obtained immediately after delivery, and trophoblasts were isolated as previously described (16, 17). In brief, placental tissue was separated by sterile dissection from different cotyledons, excluding chorionic and basal plates. Tissue pieces were washed repeatedly with ice-cold PBS to remove blood from the inter villous space. Villous tissues were digested with an equal volume of Dispase (BD Biosciences) at 37°C for 20 min. The digestion was stopped by inactivation of Dispase with EDTA. After centrifugation, tissue pellets were mixed well with DMEM (Sigma-Aldrich) and incubated on ice for 15–20 min. The supernatant containing trophoblast cells were collected and centrifuged. Isolated trophoblast cells were further purified by Percoll density gradient centrifugation (Sigma-Aldrich). The gradients were made from 45 to 15% Percoll with 5% increments in 50-mI polylpropylene tubes. Contaminated RBC were eliminated by incubation of isolated cells with lysis buffer containing 155 mM

---

### Table I. Demographic data for study subjects

<table>
<thead>
<tr>
<th></th>
<th>Normal Pregnancy</th>
<th>Mild PE</th>
<th>Severe PE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group (wk)</td>
<td>&lt;34 (n = 20)</td>
<td>34–37 (n = 13)</td>
<td>&gt;37 (n = 30)</td>
</tr>
<tr>
<td>Maternal age</td>
<td>22 ± 5</td>
<td>22 ± 4</td>
<td>22 ± 3</td>
</tr>
<tr>
<td>Racial status</td>
<td>Black 16</td>
<td>16</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>White 4</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Other 0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>BMI (≥30 kg/m²)</td>
<td>29 ± 8</td>
<td>32 ± 6</td>
<td>34 ± 10</td>
</tr>
<tr>
<td>Gestational age</td>
<td>31 ± 2</td>
<td>36 ± 1</td>
<td>40 ± 1</td>
</tr>
<tr>
<td>Primigravida (%)</td>
<td>55 23</td>
<td>23</td>
<td>40</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>118 ± 12</td>
<td>125 ± 11</td>
<td>123 ± 14</td>
</tr>
<tr>
<td>Systolic (mmHg)</td>
<td>70 ± 9</td>
<td>73 ± 8</td>
<td>74 ± 14</td>
</tr>
<tr>
<td>Diastolic</td>
<td>20 13</td>
<td>21 ± 3</td>
<td>21 ± 4</td>
</tr>
<tr>
<td>Mode of delivery</td>
<td>30 15</td>
<td>33</td>
<td>55</td>
</tr>
</tbody>
</table>

*Data are presented as mean ± SD.

---

### Table II. Maternal serum IL-16C levels in normal and preeclamptic pregnant women

<table>
<thead>
<tr>
<th></th>
<th>Normal Pregnancy</th>
<th>Mild PE</th>
<th>Severe PE</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-16 (μg/ml)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;34 wk (n = 20)</td>
<td>162 ± 12</td>
<td>144 ± 17</td>
<td>172 ± 15</td>
</tr>
<tr>
<td>&gt;37 wk (n = 30)</td>
<td>172 ± 15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>32–40 wk (n = 11)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-16 (pg/ml)</td>
<td>162 ± 12</td>
<td>144 ± 17</td>
<td>172 ± 15</td>
</tr>
<tr>
<td>Mean ± SE (range)</td>
<td>(57–334)</td>
<td>(68–299)</td>
<td>(28–395)</td>
</tr>
</tbody>
</table>

*Data are presented as mean ± SE, *p < 0.05; **, p < 0.01: severe PE vs. normal pregnancy at the same gestational age.

* p < 0.05: severe PE vs. mild PE, respectively.
Raw text:

Maternal serum IL-16C levels in normal pregnant women and in women with PE. In the normal group, the mean level of IL-16C was 177 ± 26 pg/ml in vaginal deliveries and 169 ± 18 pg/ml in cesarean section deliveries. In the preeclamptic group, the mean level of IL-16C was 451 ± 66 pg/ml in vaginal deliveries and 507 ± 78 pg/ml in cesarean section deliveries. These results suggest labor does not affect maternal IL-16C levels.

Il-16 immunostaining in maternal vessel endothelium
Maternal vessel IL-16 expression was examined by immunostaining of s.c. fat tissue sections. It is known that IL-16 gene yields two functional proteins, one from C terminus and one from N terminus. Thus, Abs against both IL-16C terminus and IL-16N terminus were used. As shown in Fig. 2, a strong vessel endothelium staining of IL-16C Ab was observed in tissue sections from women

**Results**

**Maternal serum IL-16C levels**

Maternal serum IL-16C levels in normal and preeclamptic pregnancies are shown in Table II. IL-16C levels were relatively consistent in normal pregnant women throughout the third trimester. The levels were increased in mild PE (n = 11) and significantly increased in severe PE (n = 51) compared with the normal pregnant controls (n = 63). 287 ± 46 and 515 ± 58 (p < 0.01) vs 163 ± 9 pg/ml, respectively. In severe PE, IL-16C levels were significantly higher than that in mild PE (p < 0.05) and in gestational matched normal pregnant controls, p < 0.01, respectively (Table I). These results suggest that in PE increased IL-16C levels are associated with the severity of the disease.

Fig. 1 shows the correlations of serum IL-16C levels with gestational age (upper panel) and maternal body mass index (BMI) (lower panel) in normal pregnancies and in women with PE. Our data indicates that neither gestational age nor maternal BMI is correlated with serum IL-16C levels during pregnancy.
with PE both in veins and arteries (Fig. 2, C and D). In contrast, weak or negative staining was revealed in vessel endothelium of tissue sections from normal pregnant controls (Fig. 2, A and B). In addition, neither normal tissue sections nor preeclamptic tissue sections was stained with the IL-16 Ab against N terminus (data not shown).

**IL-16 protein expression in maternal leukocytes**

Leukocyte IL-16 expressions were determined by Western blot. Again, Abs against IL-16N and IL-16C terminus were used. As shown in Fig. 3, both IL-16N and IL-16C were expressed in leukocytes from normal pregnant women. In contrast, leukocytes from women with PE expressed relatively more IL-16C than IL-16N, and the ratio of IL-16C to IL-16N was higher in leukocytes from women with PE compared with that from normal pregnant controls, $p < 0.05$.

**IL-16 production by placental trophoblasts**

Placenta releases many hormones, growth factors, and cytokines that could enter the maternal circulation during pregnancy. To further determine whether placental trophoblasts produce IL-16C and whether there is a difference for IL-16C production between normal and preeclamptic placentas, trophoblasts were isolated and IL-16C production was determined. Our results showed that trophoblasts from preeclamptic placentas ($n = 8$) produced significantly more IL-16C than the cells from normal placentas ($n = 9$), $326 \pm 67$ vs $156 \pm 26$ pg/ml/1 x $10^6$ cells, $p < 0.05$ (Fig. 4).

**Discussion**

It is well known that pregnancy-induced immune tolerance is an important immune adaptation process during normal pregnancy (18). Accumulated evidence has also shown that PE is associated with maladaptation of immune responses, with a prominent role of dysregulation in the innate immune system, probably controlled by T cells and cytokine networks at the maternal-fetal interface resulting in systemic inflammatory response triggered by trophoblast-derived stimuli (8, 18). In this study, we found that maternal serum IL-16C levels were significantly higher in women with PE than those in normal pregnant controls, which is consistent with a previous published work (19). Our data indicates that the increased IL-16C levels in PE may specifically attribute to the disease process. This notion is supported by our data that maternal IL-16C levels are neither associated with gestational age nor delivery mode in both normal and preeclamptic pregnancies. Likewise, IL-16C levels are not associated with BMI in our patient population. In addition, steroid usage seems to not affect circulating IL-16C levels in severe PE, since most of severe preeclamptic patients less than 34 wk of gestation received steroids to promote fetal lung maturity and no significant difference was found in severe PE between the groups of <34, 34–37, and >37 wk of gestation. However, our data did show that in PE, increased IL-16C levels are related to the severity of the disease, i.e., IL-16C levels were significantly higher in severe PE than in mild PE compared with the normal pregnant controls.

To investigate whether maternal vascular endothelium was involved in IL-16-related inflammatory and immune responses during pregnancy and PE, we examined IL-16 expression in maternal systemic vessels. We found a strong IL-16C staining in vessel endothelium both in arteries and veins in tissue sections from women with PE compared with that from normal pregnant women. In contrast, neither normal nor preeclamptic vessels exhibited a positive staining for IL-16N-terminal Ab. Since IL-16/CD4 preferentially induces Th1 cell migration (20), our observations not only support increased inflammatory response occurring in the maternal systemic vasculature in PE but also suggest a possible interaction of immune responses between circulating leukocytes and vascular endothelium, perhaps related to recruitment and infiltration of leukocytes into interstitial tissues and delayed apoptosis seen in PE (10, 21).

Leukocytes express IL-16. We found that leukocytes from PE exhibited a strong IL-16C expression compared with IL-16N expression relative to the leukocytes from normal pregnant controls. The C terminus exerts cytokine function, whereas the N terminus plays a role in cell cycle control. The relative strong expression of IL-16C to IL-16N ratio in leukocytes from PE indicates up-regulation of leukocyte cytokine function in PE, which is in line with increased leukocyte activation and increased inflammatory response in this pregnancy disorder. The reason for the phenomenon of down-regulation of IL-16N expression in leukocytes from PE is not known. It could be related to leukocyte apoptotic, which needs further investigation.

The source of IL-16C in the maternal circulation could be derived from multiple bases. IL-16 can be synthesized by both immune and nonimmune cells such as T cells, mast cells, and epithelial cells, etc. (1). Although, it is impossible to measure IL-16C production by maternal vascular endothelium or circulating leukocytes in vivo, enhanced IL-16C immunostaining in vessel endothelium and increased ratio of IL-16C to IL-16N protein expression in maternal leukocytes from PE suggest that both vessel endothelium and circulating leukocytes could be sources of IL-16C in the maternal circulation. Another possible source of IL-16C could be placental trophoblasts. Trophoblasts are directly bathed in the maternal blood in the placental intervillous space. It is well accepted that hormones and growth factors produced by trophoblasts could be released and enter the maternal circulation. Our results of increased IL-16C production by trophoblasts from preeclamptic placenta point out the possibility may exist.

In conclusion, in the present study, we found elevated maternal IL-16C levels in women with PE compared with the normal pregnant controls. We also observed intensive IL-16C immunostaining in maternal vessel endothelium and increased ratio of IL-16C to IL-16N expression in leukocytes from women with PE. In addition, increased IL-16C production was also found by trophoblasts from preeclamptic placentas. These data indicate that IL-16C profile is increased in both the maternal and the placental systems in PE and support the concept that increased inflammatory response occurs in this pregnancy disorder. IL-16 is a multifunctional cytokine and exerts diverse biological activities in regulation of Th1 cell function and immune tolerance. Although the role of IL-16 in PE is largely unknown, the findings of up-regulated IL-16 profile implicate that IL-16 could be an important cytokine engaged in the altered immune system and exaggerated inflammatory response in this pregnancy disorder.
Disclosures
The authors have no financial conflict of interest.

References